Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 23.36%47.73B | -3.76%167.94B | 22.99%43.27B | -15.20%42.49B | -3.59%43.49B | -12.29%38.69B | 23.41%174.5B | 2.57%35.18B | 33.72%50.11B | 51.40%45.1B |
Net interest income | 22.34%28.34B | 20.66%87.75B | 38.46%21.55B | 27.69%24.82B | 16.64%18.23B | 4.79%23.16B | 6.19%72.72B | 18.92%15.56B | -4.25%19.44B | 2.57%15.63B |
-Total interest income | 24.46%39.29B | 37.36%124.76B | 43.79%32.09B | 37.46%34.19B | 37.84%26.91B | 30.91%31.57B | 24.76%90.83B | 56.85%22.32B | 16.32%24.87B | 20.88%19.52B |
-Total interest expense | 30.30%10.95B | 104.41%37.01B | 56.04%10.55B | 72.37%9.38B | 122.78%8.69B | 318.16%8.41B | 319.36%18.11B | 489.88%6.76B | 400.37%5.44B | 325.19%3.9B |
Non interest income | 24.87%19.39B | -21.22%80.19B | 10.72%21.72B | -42.37%17.68B | -14.31%25.26B | -29.45%15.53B | 39.58%101.78B | -7.52%19.62B | 78.61%30.67B | 102.51%29.48B |
-Fees and commissions | -4.98%4.63B | 7.27%18.46B | 9.99%4.28B | 2.18%4.91B | 8.13%4.39B | 9.60%4.88B | 4.84%17.21B | 4.82%3.89B | 10.12%4.81B | 11.45%4.06B |
-Including:Fees and commission income | 3.22%6.28B | 13.74%25.71B | 15.68%6.54B | 12.49%6.45B | 13.78%6.63B | 13.01%6.08B | 2.65%22.6B | 3.93%5.66B | 4.10%5.73B | 6.04%5.83B |
-Including:Fees and commission expense | 36.37%1.65B | 34.42%7.25B | 28.25%2.26B | 66.13%1.54B | 26.74%2.24B | 29.23%1.21B | -3.75%5.39B | 2.03%1.76B | -18.95%924M | -4.58%1.77B |
-Net trading income | -10.53%68M | -68.78%300M | -58.41%47M | -59.24%64M | -69.79%113M | -76.03%76M | -53.42%961M | -63.19%113M | -69.98%157M | -10.95%374M |
-Total other operating income | 38.88%14.69B | -26.53%61.43B | 11.41%17.39B | -50.60%12.7B | -17.12%20.76B | -38.66%10.58B | 53.59%83.61B | -9.19%15.61B | 109.29%25.71B | 138.66%25.05B |
Credit losses provision | -73.39%1.13B | 138.82%4.24B | ||||||||
Operating expense | 15.17%30.84B | -2.79%131.59B | 21.86%34.71B | -16.59%31.78B | 1.89%38.32B | -14.12%26.78B | 33.27%135.37B | -6.77%28.49B | 61.87%38.09B | 61.01%37.61B |
Selling and administrative expenses | 17.98%17.64B | 16.99%66.25B | 24.61%17.72B | 18.92%16.91B | 21.76%16.67B | 3.12%14.95B | 4.80%56.63B | 5.94%14.22B | 7.05%14.22B | 4.18%13.69B |
-General and administrative expense | 17.98%17.64B | 16.99%66.25B | 24.61%17.72B | 18.92%16.91B | 21.76%16.67B | 3.12%14.95B | 4.80%56.63B | 5.94%14.22B | 7.05%14.22B | 4.18%13.69B |
Other operating expenses | 11.62%13.2B | -17.02%65.34B | 19.13%17B | -37.72%14.87B | -9.48%21.65B | -29.11%11.83B | 65.62%78.74B | -16.72%14.27B | 132.88%23.88B | 134.14%23.92B |
Income from associates and other participating interests | ||||||||||
Special income (charges) | -100.39%-68M | 10,868.28%15.61B | -159.60%-782M | -703.28%-490M | 59.34%-588M | 34,848.00%17.47B | -1,711.11%-145M | 1,897.26%1.31B | -123.46%-61M | -2,232.26%-1.45B |
Less:Restructuring and mergern&acquisition | --0 | ---17.39B | --0 | --0 | --0 | ---17.39B | --0 | --0 | --0 | --0 |
Less:Other special charges | 96.55%-3M | 108.66%132M | 101.19%17M | 177.05%169M | 140.74%33M | -22.54%-87M | -390.03%-1.52B | -2,614.04%-1.43B | 123.46%61M | 63.84%-81M |
Less:Write off | 1,320.00%71M | -1.38%1.65B | 532.23%765M | --321M | -63.65%555M | -76.19%5M | 452.65%1.67B | 656.25%121M | --0 | --1.53B |
Income before tax | -42.76%16.82B | 46.28%50.83B | 76.51%6.64B | -14.44%10.23B | -24.36%4.57B | 126.31%29.39B | -8.69%34.75B | 98.78%3.76B | -15.83%11.95B | -5.04%6.05B |
Income tax | 42.81%4.71B | 30.93%13.79B | 130.85%2.57B | 6.45%3.78B | 115.38%4.15B | -16.41%3.3B | -5.99%10.53B | 91.39%1.11B | -15.73%3.55B | 1.85%1.93B |
Net income | -53.57%12.11B | 52.96%37.04B | 53.72%4.08B | -23.26%6.45B | -89.64%427M | 188.55%26.09B | -9.82%24.21B | 102.06%2.65B | -15.87%8.4B | -7.93%4.12B |
Net income continuous operations | -53.57%12.11B | 52.96%37.04B | 53.72%4.08B | -23.28%6.44B | -89.62%428M | 188.55%26.09B | -9.82%24.21B | 102.06%2.65B | -15.87%8.4B | -7.95%4.12B |
Noncontrolling interests | 62.50%65M | -141.77%-33M | -1,712.50%-145M | 79.55%79M | -150.00%-7M | 37.93%40M | -56.59%79M | -180.00%-8M | -12.00%44M | -57.58%14M |
Net income attributable to the company | -53.75%12.05B | 53.60%37.07B | 58.65%4.22B | -23.81%6.37B | -89.41%435M | 189.03%26.05B | -9.49%24.14B | 104.46%2.66B | -15.89%8.36B | -7.60%4.11B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | ||||||||||
Net income attributable to common stockholders | -53.75%12.05B | 53.60%37.07B | 58.65%4.22B | -23.81%6.37B | -89.41%435M | 189.03%26.05B | -9.49%24.14B | 104.46%2.66B | -15.89%8.36B | -7.60%4.11B |
Gross dividend payment | ||||||||||
Basic earnings per share | -54.02%25.01 | 53.05%76.37 | 57.30%8.84 | -24.31%13.08 | -99.30%0.06 | 194.64%54.39 | -8.37%49.9 | 111.28%5.62 | -14.79%17.28 | -5.95%8.54 |
Diluted earnings per share | -53.99%24.99 | 53.14%76.31 | 57.58%8.84 | -24.23%13.07 | -99.30%0.06 | 194.58%54.32 | -8.38%49.83 | 111.70%5.61 | -14.86%17.25 | -5.95%8.53 |
Dividend per share | 0 | 20.00%24 | 40.00%14 | 0 | 0.00%10 | 0 | 25.00%20 | 0.00%10 | 0 | 66.67%10 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |